164 related articles for article (PubMed ID: 37008338)
1. Evaluation of the safety and efficacy of a Polyzene-F nanocoated coronary stent system: A systematic review and single-arm meta-analysis.
Bian J; Yang R; Wang D; Yu H; Liu Y; Liu Q
Front Cardiovasc Med; 2023; 10():1095794. PubMed ID: 37008338
[TBL] [Abstract][Full Text] [Related]
2. Five-Year Clinical Outcomes of the COBRA Polyzene F NanoCoated Coronary Stent System.
Cutlip DE; Jauhar R; Meraj P; Garratt KN; Novack V; Novack L; Maillard L; Erglis A; Stoler R; Barakat M; Silber S;
Cardiovasc Revasc Med; 2022 Aug; 41():76-80. PubMed ID: 35045942
[TBL] [Abstract][Full Text] [Related]
3. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System.
Cutlip DE; Garratt KN; Novack V; Barakat M; Meraj P; Maillard L; Erglis A; Jauhar R; Popma JJ; Stoler R; Silber S;
JACC Cardiovasc Interv; 2017 Jan; 10(2):160-167. PubMed ID: 28104210
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high-risk patients: The e-Cobra study.
Maillard L; de Labriolle A; Brasselet C; Faurie B; Durel N; de Poli F; Bosle S; Madiot H; Berland J; Belle L
Catheter Cardiovasc Interv; 2021 Jul; 98(1):45-54. PubMed ID: 32548891
[TBL] [Abstract][Full Text] [Related]
5. MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzF™ NanoCoated Coronary Stent (NCS) Implantation.
Maillard L; Vochelet F; Peycher P; Ayari A; Barra N; Billé J; Joly P; Silvestri M; Sévilla J; Tavildari A
Cardiovasc Revasc Med; 2020 Jun; 21(6):785-789. PubMed ID: 31780418
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. COBRA PzF™ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies?
Cornelissen A; Sakamoto A; Sato Y; Kawakami R; Mori M; Kawai K; Kutyna M; Fernandez R; Ghosh S; Barakat M; Virmani R; Finn A
Future Cardiol; 2022 Mar; 18(3):207-217. PubMed ID: 34521223
[TBL] [Abstract][Full Text] [Related]
8. Reduction of late in-stent stenosis in a porcine coronary artery model by cobalt chromium stents with a nanocoat of polyphosphazene (Polyzene-F).
Stampfl U; Sommer CM; Thierjung H; Stampfl S; Lopez-Benitez R; Radeleff B; Berger I; Richter GM
Cardiovasc Intervent Radiol; 2008; 31(6):1184-92. PubMed ID: 18704573
[TBL] [Abstract][Full Text] [Related]
9. Immediate and 1-year follow-up with the novel nanosurface modified COBRA PzF stent.
Maillard L; Tavildari A; Barra N; Billé J; Joly P; Peycher P; Silvestri M; Vochelet F
Arch Cardiovasc Dis; 2017 Dec; 110(12):682-688. PubMed ID: 29102364
[TBL] [Abstract][Full Text] [Related]
10. Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE).
Colleran R; Joner M; Cutlip D; Urban P; Maeng M; Jauhar R; Barakat M; Michel JM; Mehran R; Kirtane AJ; Maillard L; Kastrati A; Byrne RA;
Cardiovasc Revasc Med; 2022 Jan; 34():17-24. PubMed ID: 33608239
[TBL] [Abstract][Full Text] [Related]
11. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
12. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial.
Tamburino C; La Manna A; Di Salvo ME; Sacchetta G; Capodanno D; Mehran R; Dangas G; Corcos T; Prati F
JACC Cardiovasc Interv; 2009 Mar; 2(3):197-204. PubMed ID: 19463426
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in patients treated with the zotarolimus-eluting stent at a tertiary medical center.
Shammas NW; Shammas GA; Lemke J; Miller S; Meriner S
J Invasive Cardiol; 2012 Jun; 24(6):256-60. PubMed ID: 22684377
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies.
Gu H; Hua K; Li W; Wang Y; Yang J
Int J Cardiol; 2015 Dec; 201():552-60. PubMed ID: 26334379
[TBL] [Abstract][Full Text] [Related]
15. Crush versus Culotte stenting techniques for coronary bifurcation lesions: A systematic review and meta-analysis of clinical trials with long-term follow-up.
Chen E; Cai W; Chen LL
Medicine (Baltimore); 2019 Apr; 98(14):e14865. PubMed ID: 30946314
[TBL] [Abstract][Full Text] [Related]
16. Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome: a meta-analysis.
Yuan H; Wu Z; Lu T; Wei T; Zeng Y; Liu Y; Huang C
BMJ Open; 2022 Jun; 12(6):e058075. PubMed ID: 35676012
[TBL] [Abstract][Full Text] [Related]
17. Impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 16 randomized trials.
Zhang YJ; Zhu LL; Bourantas CV; Iqbal J; Dong SJ; Campos CM; Li MH; Ye F; Tian NL; Garcia-Garcia HM; Serruys PW; Chen SL
J Cardiol; 2014 Sep; 64(3):185-93. PubMed ID: 24560821
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of zotarolimus-eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE-DIABETES CHINA Study.
Zhu Z; Wu Y; Shen Z; Xu Y; Li Y; Wang Y; Su X; Li B; Jiang T; Jiang J; Wang L; He S; Li X; Li H; Liu Y; Zhou Y; Tang Q; Chen Y; Fang W; Jiang L; Lu C; Guo J; Zhang J; Chen S; Xia Y; Zheng H; Wang B; Zhang D; Feng L; Tang L; Xu P; Liu X; Zhang R;
J Diabetes; 2019 Mar; 11(3):204-213. PubMed ID: 30070032
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
